JANX: Truist Assumes Buy
Truist Securities analyst assumes Janux Therapeutics with a Buy rating and lowers Price Target to $26
Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ: JANX ) with a Buy rating and lowers Price Target of $26.